Loading...
•
Jun 30, 2021
Tenaya Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided business updates.
Key Takeaways
Tenaya Therapeutics reported its Q2 2021 financial results, highlighting a successful IPO that raised $207 million and progress in advancing their gene therapy and precision medicine platforms.
TN-201 received Orphan Drug Designation from the FDA.
Expanded leadership team with key appointments.
Completed Initial Public Offering, raising $207 million in gross proceeds.
Advanced TN-201 and TYA-11631 programs towards INDs in 2022.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya expects its current cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund its current operating plan at least into the 2nd half of 2023.